Genotype-guided antiplatelet therapy using CYP2C19 POC genotyping prior to PCI in ACS/CAD patients may reduce the risk of recurrent myocardial infarction and composite MACEs compared to standard treatment, highlighting the importance of POC genotyping for facilitating rapid and effective therapeutic decision-making. This evidence concerns the gene CYP2C19 and myocardial infarction.